retatrutide phase 3 2025 triple agonist glp-1 gip glucagon What Makes Powder a Breakthrough Triple-Agonist API? Lilly's triple agonist delivers up

While there are limitations, the promise of improved diabetes management, cardiovascular benefits, and new formulations places GLP-1 agonists at the forefront of diabetes care

doi: 10.1126/scitranslmed.aar7047 [DOI] [PubMed] [Google Scholar] 101

Because beta-cell function is essential for proper intrinsic insulin response to increased BG levels, therapies that have the potential to improve cell function may help slow the progression of insulin resistance

Patients should contact their GP or diabetes specialist nurse if they experience unexpected changes in blood glucose control, significant gastrointestinal symptoms, or concerns about dietary modifications whilst on GLP-1 therapy

doi: 10.1007/s10557-019-06915-8 90 VermaMKGoelRKrishnadasNNemmaniKVS

Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia